(HealthDay)—Men exposed to antidiabetic medications do not have different prostate-specific antigen (PSA) levels, and prostate cancer detection rates at biopsy do not differ regardless of trigger PSA levels, according to a study published online Nov. 6 in JAMA Network Open. Kerri Beckmann, Ph.D., from King’s College London, and colleagues examined the correlations of antidiabetic medication...